M. Digennaro

发表

BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy.

A. Paradiso, S. Tommasi, F. Schittulli, 2005, Mutation research.

BRCA 1 / 2 and clinical outcome in a monoinstitutional cohort of women with hereditary breast cancer

S. Tommasi, A. Paradiso, M. Digennaro, 2013 .

The Role of Circulating Adiponectin and SNP276G>T at ADIPOQ Gene in BRCA-mutant Women

A. Paradiso, P. Pasanisi, S. Tommasi, 2020, Cancer Genomics & Proteomics.

Sentinel Lymph Node Metastasis on Clinically Negative Patients: Preliminary Results of a Machine Learning Model Based on Histopathological Features

M. C. Comes, A. Paradiso, R. Massafra, 2021, Applied Sciences.

Comment on ‘Renewed interest in the progesterone receptor in breast cancer’

S. Tommasi, A. Paradiso, M. Digennaro, 2017, British Journal of Cancer.

Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease

B. Bonanni, L. Boni, M. Digennaro, 2021, Clinical Cancer Research.

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia

B. Bonanni, L. Boni, M. Digennaro, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lifestyle Characteristics in Women Carriers of BRCA Mutations: Results From an Italian Trial Cohort.

A. Paradiso, P. Pasanisi, S. Tommasi, 2020, Clinical breast cancer.

Adipokines in hereditary breast cancer patients and healthy relatives

S. Tommasi, A. Paradiso, M. Digennaro, 2017, Oncotarget.

Spectrum of Germline Pathogenic Variants in BRCA1/2 Genes in the Apulian Southern Italy Population: Geographic Distribution and Evidence for Targeted Genetic Testing

S. Tommasi, A. Paradiso, M. Digennaro, 2021, Cancers.

Attitude towards genetic testing for breast cancer susceptibility: a comparison of affected and unaffected women.

A. Paradiso, S. Tommasi, F. Schittulli, 2010, European journal of cancer care.

Abstract PD3-08: Effects of low dose tamoxifen on circulating risk biomarkers in a phase III trial in breast pre-invasive disease

B. Bonanni, L. Boni, M. Digennaro, 2020 .

TGFbeta and miRNA regulation in familial and sporadic breast cancer.

S. Tommasi, R. Lacalamita, M. Digennaro, 2017, Oncotarget.

BRCA1/2 and clinical outcome in a monoinstitutional cohort of women with hereditary breast cancer.

S. Tommasi, A. Paradiso, M. Digennaro, 2014, Oncology reports.

Can harmful lifestyle, obesity and weight changes increase the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers? A Mini review

A. Paradiso, P. Pasanisi, S. Tommasi, 2021, Hereditary cancer in clinical practice.

Hereditary and non-hereditary branches of family eligible for BRCA test: cancers in other sites

A. Paradiso, S. Tommasi, M. Digennaro, 2017, Hereditary cancer in clinical practice.

Molecular and in silico analysis of BRCA1 and BRCA2 variants.

S. Tommasi, A. Paradiso, F. Schittulli, 2008, Mutation research.

Analysis of the Reasons for Accepting or Declining Participation in Genetic Research for Breast Cancer: A Hospital-Based Population Study

A. Paradiso, F. Schittulli, M. Bruno, 2004, Tumori.

BRCA germline mutation test for all woman with ovarian cancer?

A. Paradiso, I. Berindan‐Neagoe, S. Tommasi, 2019, BMC Cancer.

Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection

A. Paradiso, S. Tommasi, M. Digennaro, 2020, Frontiers in Oncology.

Somatic BRCA Mutation in Cholangiocarcinoma Patient Utilized to Individualize an HBOC Syndrome

A. Paradiso, S. Tommasi, M. Digennaro, 2019 .

BRCA germline mutation test for all woman with ovarian cancer?

A. Paradiso, I. Berindan‐Neagoe, S. Tommasi, 2019, BMC Cancer.

Remote vs in-person BRCA1/2 non-carriers test disclosure: patients’ choice during Covid-19 pandemic restriction

A. Paradiso, M. Digennaro, S. De Summa, 2022, Familial Cancer.

miRNA deregulation and relationship with metabolic parameters after Mediterranean dietary intervention in BRCA-mutated women

P. Pasanisi, S. Tommasi, M. Digennaro, 2023, Frontiers in Oncology.

Oncological genetic counseling (OGC) for high-risk hereditary cancer: what can hospital anxiety and depression scale (HADs) tell us?

A. Paradiso, M. Digennaro, A. Fanizzi, 2020, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study

B. Bonanni, M. Digennaro, L. Cortesi, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular and in silico analysis of BRCA1 and BRCA2 variants.

S. Tommasi, A. Paradiso, F. Schittulli, 2008, Mutation research.